ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Acute MI Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01580566
Recruitment Status : Recruiting
First Posted : April 19, 2012
Last Update Posted : April 11, 2017
Sponsor:
Information provided by (Responsible Party):
Ingrid Hopper, Monash University

Brief Summary:

The purpose of this study is to determine if a sizable myocardial infarction (heart attack) results in negative changes to renal structure and function (i.e. has a negative impact on the kidneys).

To determine if the renal response to a myocardial infarction is a predictor of the patients future health.


Condition or disease
Myocardial Infarction Kidney Function

Detailed Description:
Chronic heart and kidney disease are increasingly common in Western society. Both conditions are associated with frequent hospitalisation and increased mortality. Furthermore, there are mechanistic reasons why one condition may beget the other; the so-called "cardiorenal syndrome". The investigators therefore wish to determine if a sizable myocardial infarction (heart attack) results in negative changes to renal structure and function (i.e. has a negative impact on the kidneys). The investigators also wish to determine if the renal response to a myocardial infarction is a predictor of the patients future health. To do this the investigators will measure markers of kidney function at the time of the heart attach, at discharge, 1 month, 6 months and 12 months and correlate this with the patients clinical condition.

Study Type : Observational
Estimated Enrollment : 160 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Renal Structural, Functional and Cytokine Responses to Acute Myocardial Injury in Man
Study Start Date : March 2012
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack
U.S. FDA Resources

Group/Cohort
Group 1 - Control
Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as "control" for renal injury subjects.
Group 2 - stable CAD or non-Q wave MI
Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
Group 3 - Acute STEMI without chronic kidney disease
Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
Group 4 - Acute STEMI with kidney disease
Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).



Primary Outcome Measures :
  1. changes in renal function and structure [ Time Frame: Baseline, discharge, 1 month, 6 months and 12 months ]

Secondary Outcome Measures :
  1. renal response to myocardial infarction [ Time Frame: baseline, discharge, 1 month, 6 months and 12 months ]

Biospecimen Retention:   Samples With DNA
Blood samples to measure bio-markers


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who have presented to the Emergency Department with chest pain caused by a possible myocardial infarction.
Criteria

Inclusion Criteria:

Age > 18 years

Have provided written informed consent

Group 1:

  • Non-Q wave MI patients
  • normal cardiac and renal function
  • No use of contrast
  • eGFR > 60ml/min

Group 2:

  • Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI
  • normal cardiac and renal function
  • eGFR > 60ml/min

Group 3:

  • Acute STEMI Full thickness infarct (STEMI)
  • eGFR ≥ 60ml/min

Group 4:

  • Acute STEMI Full thickness infarct (STEMI)
  • eGFR < 60ml/min

Exclusion Criteria:

  • Unable or unwilling to comply with the study protocol
  • Underlying medical condition which, in the opinion of the investigator, will effect the safely or efficacy of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01580566


Contacts
Contact: Henry Krum, MBBS FRACP PhD +613 9903 0042 henry.krum@monash.edu

Locations
Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Henry Krum, MBBS FRACP PhD    +613 9903 0042    henry.krum@monash.edu   
Principal Investigator: Henry Krum, MBBS FRACP PhD         
Sponsors and Collaborators
Monash University
Investigators
Principal Investigator: Henry Krum, MBBS FRACP PhD Alfred Hospital/Monash.University
Principal Investigator: Henry Krum, MBBS FRACP PhD Alfred Hospital/Monash University

Responsible Party: Ingrid Hopper, Seniour Lecturer, Monash University
ClinicalTrials.gov Identifier: NCT01580566     History of Changes
Other Study ID Numbers: CP-03/11
First Posted: April 19, 2012    Key Record Dates
Last Update Posted: April 11, 2017
Last Verified: April 2017

Keywords provided by Ingrid Hopper, Monash University:
Myocardial Infarction (MI)
Kidney function
bio-markers

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases